TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04159909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Nerve Stimulation
Description: 510(K) number: K110390 vagus nerve for 5 minutes twice a day for 4 consecutive days

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: sham stimulation (no electrical current) for 5 minutes twice a day for 4 consecutive days
Study: NCT05962801

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lumoral device, Lumorinse
Description: Regular use of dual-light photodynamic therapy at home
Study: NCT05271552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501
Description: Sublingual Film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501
Description: Sublingual Film

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Sublingual Placebo Film
Study: NCT05277103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exploring predictors of response to a peer-mediated communication intervention for minimally verbal preschoolers with ASD
Description: The intervention, Stay-Play-Talk with iPad, incorporates SGD instruction and peer training, both demonstrated to be effective in increasing communication and social interactions of preschool-age children with ASD. Children with ASD will be provided with an iPad with Touch Chat voice output app (the SGD) to use throughout the project. Two peers are recruited for each child with ASD. Research staff will implement peer training for three 30-min sessions, with peers taught to: STAY - sit close; PLAY- share and take turns; and TALK with iPad - look and listen/push and talk. After peers are trained, they will take turns engaging in common preschool games and preferred play activities with one assigned child with ASD (1 child:1 peer). Treatment will be provided for 15-20 min, twice per week for 8 weeks in the classroom.
Study: NCT04955444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality improvement bundle
Description: The quality improvement bundle consists of (1) patient education, (2) provider education, and (3) EHR enhancements including order sets and best practice alerts.
Study: NCT05416541

Intervention type: BEHAVIORAL
Intervention: social media
Description: ASA I-II, who speaks and writes Turkish and do not have psychiatric illness patients will attend the study.
Study: NCT06261580

Intervention type: DIAGNOSTIC_TEST
Intervention: TEG 6s Citrated K, KH, RTH, and FFH Cartridge
Description: The TEG® 6s uses the Global Hemostasis with Heparin Neutralization (HN) Cartridge to test the hemostasis properties of citrated blood samples using four different assays/reagents simultaneously, one in each of the four cartridge channels.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clauss Fibrinogen
Description: Fibrinogen, also known as Factor I, is a plasma protein that can be transformed by thrombin into a fibrin gel (the clot). Fibrinogen is synthesized in the liver and circulates in the plasma as a disulfide-bonded dimer of 3 subunit chains. The biological half-life of plasma fibrinogen is 3 to 5 days.
Study: NCT04014179

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert HCV Viral Load Fingerstick
Description: The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is an in vitro nucleic acid amplification test designed for the quantitation of Hepatitis C Virus (HCV) DNA in human whole blood using the automated GeneXpert Systems. The HCV RNA result from the Xpert test will be used to initiate HCV treatment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aptima HCV Quant DX Assay
Description: The Aptima HCV Quant Dx assay is a real-time transcription-mediated amplification test.~The assay is used for both detection and quantitation of hepatitis C virus (HCV) RNA in fresh and frozen human serum and plasma from HCV-infected individuals, and in this study from dried blood spots. The HCV RNA result from the Aptima assay will be used to initiate HCV treatment.
Study: NCT06323551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother's Smell
Description: The mother of each baby whose heel blood will be taken will be given a specially made cover made of 100% cotton yarn, sterilized the day before, and the mother will be asked to put the cover on her bare skin (on her bare skin) after the shower and to keep the cover on the mother's chest for one night (8 hours). one).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother's Breast Milk Smell
Description: In the study group that will be made to smell the scent of breast milk, the procedures for the scent of the mother will be carried out in the same way, and 20 drops of each baby's own mother's milk will be dropped onto the diaper.
Study: NCT05687357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: IV infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: TOMO/VMAT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: TOMO/VMAT
Study: NCT05399914

Intervention type: OTHER
Intervention: S-NIPPV
Description: Synchronized noninvasive positive pressure ventilation during the first 10 minutes after birth.
Study: NCT04550338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Oral administration of blinded medications

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of blinded medications
Study: NCT05599620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARE
Description: AWARE addresses alcohol use, sexual distress, and sexual assault risk among college women with a history of sexual victimization.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Health Promotion
Description: General Health Promotion is an attention and dose matched intervention with no overlapping components with AWARE.
Study: NCT06476613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Permissive Hypotension
Description: Patients will be randomized in 1:1 fashion to either a) Permissive Hypotension (MAP target \> 60mmHg) or b) Usual Care. The duration of the intervention will extend until the patient no longer needs vasopressors to maintain prespecified MAP.
Study: NCT04886622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT2216
Description: DT2216 will be administered by intravenous infusion
Study: NCT05929521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C-PrEP+
Description: Rather than a one-on-one PrEP care visit, a cohort of 8-12 patients meet with the same providers at each visit for individual health assessments, linkages to services, and 75-90 minutes of group interactive learning and skill-building that centers patients' experiences. This approach to healthcare has great potential meet sex workers' HIV prevention needs, including optimal use of PrEP
Study: NCT06504316

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRRT filter
Description: The subjects will be accepted CRRT using a filter for 72 hours. The subjects will be continued to CRRT or not after 72 hours (the first session of treatment) according to clinical situation by clinician decision. CRRT prescription: 1 Blood purification access: Central vein indwelling double lumen catheter (diameter 11F-13.5F) can be placed in femoral vein, internal jugular vein and subclavian vein; 2.Anti-coagulation prescription: Anticoagulant is used according clinical situation by clinician decision (such as heparin, sodium citrate, and so on); 3. Modality of CRRT: CVVH: blood flow 150-200ml/min; replacement fluid flow 30-35ml/kg/h (100% post-dilution).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRRT filter
Description: The subjects will be accepted CRRT using a filter for 72 hours. The subjects will be continued to CRRT or not after 72 hours (the first session of treatment) according to clinical situation by clinician decision. CRRT prescription: 1 Blood purification access: Central vein indwelling double lumen catheter (diameter 11F-13.5F) can be placed in femoral vein, internal jugular vein and subclavian vein; 2.Anti-coagulation prescription: Anticoagulant is used according clinical situation by clinician decision (such as heparin, sodium citrate, and so on); 3. Modality of CRRT: CVVH: blood flow 150-200ml/min; replacement fluid flow 30-35ml/kg/h (100% post-dilution).
Study: NCT04939961

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hericium erinaceus
Description: 6 capsules per day, 3 times two after breakfast, lunch and dinner

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 capsules per day, 3 times two after breakfast, lunch and dinner
Study: NCT05151705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031 injection
Description: Treatment group A:HR17031 injection; 10U/0.024mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031 injection
Description: Treatment group B: HR17031 injection; 10U/0.024mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031 injection
Description: Treatment group C: HR17031 injection; 10U/0.024mg
Study: NCT05564728

Intervention type: OTHER
Intervention: Conversational Agent/Chatbot App
Description: Well Feet is developed based on adaptive learning frameworks to deliver diabetes foot care education through a conversational agent. The learning path for each participant will be customised based on their responses to pre-module quizzes.
Study: NCT04971681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency repetitive transcranial magnetic stimulation (rTMS)
Description: Subjects will receive one session of low frequency repetitive transcranial magnetic stimulation (rTMS) targeting the medial prefrontal cortex (mPFC), within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 110% of motor threshold (MT), for a total of 1200 pulses

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low frequency repetitive transcranial magnetic stimulation (rTMS)
Description: Subjects will receive one session of low frequency repetitive transcranial magnetic stimulation (rTMS) targeting the medial prefrontal cortex (mPFC), within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 110% of motor threshold (MT), for a total of 1200 pulses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
Study: NCT04989465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational 23-valent PPV
Description: The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control 23-valent PPV
Description: The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd. 25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of light disodium phenol phosphate, sodium hydrogen phosphate and sodium chloride per injection
Study: NCT04748874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate mNC-FET
Description: In the immediate arm, patients undergo mNC-FET in the menstrual cycle immediately following oocyte retrieval and failed fresh embryo transfer or freeze-all.
Study: NCT06127550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active taVNS
Description: low level stimulation to the auricular branch of the vagus nerve

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham taVNS
Description: device placed with no current administered
Study: NCT05794308

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Relational Chatbot Physical Activity Intervention
Description: Mobile app-based intervention. Participants will engage in a daily chat with a physical activity promotion chatbot. The chatbot does not, or only minimally, provide relational behavioral cues. Participants will view their progress of daily step counts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relational Chatbot Physical Activity Intervention
Description: Mobile app-based intervention. Participants will engage in a daily chat with a physical activity promotion chatbot. The chatbot provides relational behavioral cues. Participants will view their progress of daily step counts.
Study: NCT06079333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib/trametinib
Description: braf/mek-inhibition
Study: NCT05238389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-based upper limb robotic therapy
Description: Patients will be treated using MOTORE, a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints. The intervention will consist of 30 sessions, 1 per day and 5 per week. Therefore, each patient will be treated for 6 weeks~The parameters of the serious games will be proposed by a Decision Support System (DSS), based on an AI-based algorithm trained using data collected during a previous Randomized Controlled Trial.~The DSS will be fed, at the enrollment, with patient's demographics, clinical characteristics, clinical scales and kinematic/kinetic data measured by the robot during an evaluation session (unassisted reaching movements) and updated every 2 sessions with kinematic/kinetic data only, to tailor the treatment to the patient's current abilities.~The therapists will be free to use or not the suggested parameters, on the basis of their previous experience with the robot (over 3 years).
Study: NCT05918718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: assessment of the efficacy of Letrozole in treatment of ectopic pregnancy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: assessment of the efficacy of Letrozole in treatment of ectopic pregnancy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: methotrexate
Study: NCT05605626

Intervention type: OTHER
Intervention: the better retaining of skills
Description: identify which teaching program has the better retaining of skills

Intervention type: OTHER
Intervention: the better retaining of skills
Description: identify which teaching program has the better retaining of skills
Study: NCT05346575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Obesity Treatments to Adult Learners (TOTAL)
Description: TOTAL includes both video component and motivational telemedicine calls delivered via VA Video Connect (VVC) by a study interventionist. We will invite study participants to watch the 18-minute video at least once. The motivational component of TOTAL will consist of three telemedicine-based (VVC), one-on-one, 30-minute calls at 1 week, 6 months, and 12 months after randomization. This timing was selected so Veterans would have regular interactions with the interventionist within one year of initiating the intervention. Each motivational session will be tailored to where Veterans are in the treatment initiation process. Electronic outcome assessment surveys will be sent to the participants at baseline, at each motivational telemedicine visit, and for the 18 month assessment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The usual care group will be electronically sent the 1-week, 6-month, 12-month, 18-month assessments. All usual care participants will be offered the opportunity to watch the educational video component of TOTAL after the final outcome assessment is performed (18 months post-randomization). Veterans in the usual care arm will also have access to the MOVE! program via referrals from the PCP or self-referral to MOVE!. If they initiate treatment in MOVE!, they may progress through MOVE! and receive obesity medications or be referred for bariatric surgery if they choose to do so.
Study: NCT05003479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine (Vero Cells), Inactivated
Description: 2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
Study: NCT05345353

Intervention type: BEHAVIORAL
Intervention: Fat For Fight (FFF), The Aarhus Protocol
Description: A multicomponent family-centered lifestyle intervention which included visits at home and weekly supervised physical activity. Intervention duration - one year maximum

Intervention type: BEHAVIORAL
Intervention: The Children's Obesity Clinic Treatment (TCOCT), The Randers Protocol
Description: A multicomponent family-centered lifestyle intervention which included repeatedly visits (up to 8 times / year). Intervention duration - three years maximum
Study: NCT05719649

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactic acid bacteria NTU 101
Description: One NTU 101 Lactic Acid Bacteria Vegetable Capsule a day for a total of 12 weeks.~Product ingredients: microcrystalline cellulose, corn starch, NTU 101 Lactobacillus paracasei subsp. paracasei NTU 101 (1.8 x 10\^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin was used as a placebo
Study: NCT04984967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of peripheral venous catheter with micro-guide
Description: After antisepsis, the vein is punctured using a needle. Then the micro-guide is inserted to the first landmark, which indicates the passage of the micro-guide beyond the end of the needle. After the needle removed, the peripheral venous catheter is placed on the micro-guide. The guide is then removed, the peripheral venous catheter can be used.

Intervention type: OTHER
Group type: OTHER
Intervention: Classic insertion of peripheral venous catheter, without micro-guide
Description: After antisepsis, the catheter is introduced into the vein by a needle which is subsequently removed while the catheter remains in place.
Study: NCT05852080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multilevel system intervention based on information platform
Description: 1. Standardized templates of medical record~2. Continuous medical quality control and feedback system: the hospital included in the study upload the medical records of all AIS patients by medical records scanning system. Quality control platform of Cerebral apoplexy in Zhejiang province extracts and analyze the data through the computer and calculates the percentage of stroke of undetermined cause.~3. Team collaboration based on video conferencing: hospitals will receive corresponding suggestions for their improvement from experts online.~4. Enhanced feedback incentives
Study: NCT05555875

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IntelliCare Plus
Description: Mobile-app-based digital mental health intervention for individuals struggling with depression and/or anxiety. The app reflects components of evidence-based psychological treatments such as cognitive-behavioral therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntelliCare Plus
Description: Mobile-app-based digital mental health intervention for individuals struggling with depression and/or anxiety. The app reflects components of evidence-based psychological treatments such as cognitive-behavioral therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntelliCare Plus
Description: Mobile-app-based digital mental health intervention for individuals struggling with depression and/or anxiety. The app reflects components of evidence-based psychological treatments such as cognitive-behavioral therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntelliCare Plus
Description: Mobile-app-based digital mental health intervention for individuals struggling with depression and/or anxiety. The app reflects components of evidence-based psychological treatments such as cognitive-behavioral therapy.